Leeds Teaching Hospitals NHS Trust

Leeds Teaching Hospitals NHS Trust, (UK) Performs Non-Invasive Histotripsy in Patient with Primary Solid Renal Tumor MINNEAPOLIS, March 30, 2023 /PRNewswire/ -- HistoSonics, ( ), the developer of a non-invasive platform and novel sonic beam therapy called histotripsy, announced today the first kidney patient has been treated using the Company's histotripsy platform. The procedure was performed in Leeds, UK, by Professor Tze Min Wah, Senior Consultant Radiologist and Clinical Lead for Interventional Oncology Program at Leeds Teaching Hospitals NHS Trust, UK. This procedure marks the initial treatment in the HistoSonics sponsored "CAIN" Trial which is a Phase I prospective, multi-center study designed to evaluate the safety and technical success of the Company's histotripsy system in targeting and destroying primary solid renal tumors, completely non-invasively and without the need for incisions or needles. The trial is named in honor of Charles Cain PhD, former Chair of Biomedical Engineering at the University of Michigan, co-inventor of histotripsy, and co-founder of HistoSonics, who passed away in March of 2020. "This first treatment is a significant milestone for the Company as it represents expansion into our second active clinical application (after liver) and supports our mission to deliver histotripsy to patients who may potentially benefit from its unique capabilities," commented Mike Blue, President, and CEO of HistoSonics. Blue added, "Our goal is to enable physicians to precisely target and destroy kidney tumors with our novel, noninvasive solution, avoiding the morbidity and complications seen with current invasive surgery or ablative techniques." Current kidney therapies such as partial nephrectomy and thermal ablation are invasive and exhibit complications from bleeding and infection that non-invasive histotripsy may avoid. While surgical intervention is the "gold standard" in removing kidney tumors, a non-invasive approach with histotripsy provides the potential to destroy targeted tissue without damaging non-targeted kidney tissue. Additionally, histotripsy's purely mechanical mechanism of cellular destruction could preserve function of the kidney's urine collecting system and eliminate certain complications seen with existing invasive approaches. Professor Tze Min Wah commented, "I was delighted to lead the clinical team in carrying out this world's first kidney tumor treatment using histotripsy and a real privilege to have the trust of the patient and their family in translating this innovative technology into our clinic. The CAIN Trial represents a significant milestone for treatment of solid renal tumors with histotripsy as a needle-less technology and is a paradigm shift from this point onwards for generally." HistoSonics' image guided sonic beam therapy system uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control. The science of histotripsy uses focused sound energy to produce controlled acoustic cavitation that mechanically destroys and liquifies targeted tissue at sub-cellular levels. The company believes that the novel mechanism of action of their proprietary technology provides significant advantages to patients, including the ability of the treatment site to recover and resorb quickly. Uniquely, the HistoSonics' platform also provides physicians the ability to monitor the destruction of tissue under continuous real-time visualization and control, unlike any modality that exists today. HistoSonics histotripsy systems are not currently available for sale. Any use is limited to clinical investigations. The HistoSonics Edison™ System is pending FDA review for a destruction of liver tissue indication. The CAIN Trial is expected to support a future expansion of the indication to include the destruction of kidney tissue. About HistoSonics HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on the continued development of its Edison™ Platform, global clinical studies, and new strategic projects including future clinical applications and platforms. HistoSonics has offices in Ann Arbor, Michigan and Minneapolis, MN. For more information please visit: View original content to download multimedia: SOURCE HistoSonics, Inc.

Women’s health startup Inne raises $10M Berlin-based healthtech startup Inne has raised an additional $10 million (€9.3M) in funding led by DSM Venturing. Borski Fund and Calm Storm Ventures also participated in the round, along with angels Taavet Hinrikus (Wise), Dr Fiona Pathiraja and Rolf Schromgens (Trivago). Inne will use the investment to continue to develop its mini lab and platform to serve more areas of women’s health and expand into the U.S. The startup is expanding its progesterone-tracking feature to perimenopause and adding the ability to analyze stress through a cortisol tracking strip. Eirini Rapti, founder and CEO, Inne, said, “Inne can be the trusted partner for millions of women around the world, democratizing the access to insight and information.” NuvoAir launches remote asthma service in collaboration with 17 NHS trusts Swedish startup NuvoAir is collaborating with 17 NHS trusts to launch a virtual asthma assessment service. The service uses respiratory physiologists and connected home-monitoring technology to assess lung function variability, and a sensor to track inhaler use and technique. NuvoAir founder and CEO, Lorenzo Consoli said: “We’re excited to partner with the NHS and forward-looking clinicians to redesign new care pathways for people with asthma. By blending high touch with high-tech, we’re able to help patients get on the right treatment at the right time to prevent asthma exacerbations.” British digital health startup Healum launches research network U.K.-based startup Healum has launched a research community for people with long-term health conditions, such as diabetes and heart disease. Patients will be invited to shape the ways the newly developed AI technology uses their information and will have the option to share their health data to help others with the same conditions. The community is also open to healthcare providers and researchers who are interested in partnering with patients to learn what approaches work best in achieving health outcomes. Jonathan Abraham, CEO and cofounder, Healum, said: “AI has the potential to unlock many benefits for healthcare if it is guided by the wisdom of the people that deliver and use services.” Leeds Teaching Hospitals NHS Trust joins Leeds-Israel Innovation Healthtech Gateway Leeds Teaching Hospitals NHS Trust has announced it is a partner in the newly launched Leeds-Israel Innovation Healthtech Gateway. This initiative, the first of its kind in the U.K., aims to foster collaboration and support high-growth Israeli tech firms on their expansion to the U.K. Dame Linda Pollard, chair, Leeds Teaching Hospitals NHS Trust, said: “This is a fantastic initiative which will enable us to strengthen our links with Israel and the health sector businesses which are at the leading edge of innovation in healthcare technology." Ongoing IT issues disrupt four NHS hospitals in Greater Manchester An IT system failure at NHS hospitals in Greater Manchester, U.K., has led to some patients waiting for 11 hours in the emergency department. Dr Chris Brookes, deputy CEO and CMO, Northern Care Alliance NHS Trust, said on Wednesday (25) they were still working to resolve “significant IT issues” affecting digital systems at hospitals at Oldham, Bury and Rochdale, as well as North Manchester General Hospital which is run by Manchester University NHS Foundation Trust. He added that patients may experience delays across services, but personal data held by the NHS and trust was “secure and unaffected.” AI startup VeinCV gets free access to GPU cloud Solutions Russian medtech startup VeinCV has been given free access to the VK Cloud Solutions platform, which is based on graphics accelerators (GPUs). The spin-out from Moscow’s Skolkovo Institute of Science and Technology has developed a medical-imaging system that makes blood draws easier by using neural networks to analyze near-infrared images of veins and project a venous pattern onto a patient’s body. Oleg Rogov, cofounder and CEO, VeinCV, said: "Using VK Cloud Solutions GPUs, the VeinCV team was able to develop and train segmentation models, improving the quality of data received from VeinCV systems by 11%. The image has become better, and cloud computing has accelerated and simplified the further development of the project.”